Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 17/20 | 0.77 |
| ▸ | CDK2 | P24941 | 15/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 9/20 | 0.77 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.51 |
| ▸ | FLT3 | P36888 | 1/20 | 0.51 |
| ▸ | GSK3A | P49840 | 1/20 | 0.51 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14368146 | 0.91 | AURKA (0.80) | AURKACDK2MAPK1MAP3K7FLT3 | |
| SCHEMBL16893016 | 0.88 | AURKA (0.59) | AURKACDK2MAPK1 | |
| SCHEMBL14368148 | 0.87 | AURKA (0.58) | AURKACDK2MAPK1MAPK10ROCK1 | |
| SCHEMBL1226700 | 0.87 | AURKA (1.00) | AURKACDK2MAPK1MAP3K7FLT3 | |
| SCHEMBL5403938 | 0.85 | AURKA (0.53) | AURKACDK2MAPK1 | |
| SCHEMBL5403698 | 0.81 | AURKA (0.63) | AURKACDK2MAPK1 | |
| SCHEMBL13580632 | 0.79 | AURKA (0.63) | AURKACDK2MAPK1MAPK10ROCK1 | |
| SCHEMBL13580648 | 0.79 | AURKA (0.67) | AURKACDK2MAPK1MAPK10 | |
| SCHEMBL14368142 | 0.79 | AURKA (0.84) | AURKACDK2MAPK1MAP3K7FLT3 | |
| SCHEMBL16893118 | 0.79 | AURKA (0.60) | AURKACDK2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1363906-B1 | HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF | VERTEX PHARMA (US) | 2015-07-15 | — | — | EP | disclosed |
| US-20070265263-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | CAO JINGRONG | 2007-11-15 | — | — | US | disclosed |
| US-20070265263-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | CAO JINGRONG | 2007-11-15 | — | — | US | disclosed |
| US-7253187-B2 | Heterocyclic inhibitors of ERK2 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-07 | — | — | US | disclosed |
| US-7253187-B2 | Heterocyclic inhibitors of ERK2 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265263-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | MAPK1, MAPK3, MAPKAPK2 | AURKA 3692/4885CDK2 66/4885MAPK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.